Eisai Oncology to Present New Research on Product Portfolio and Pipeline at ASCO Annual Meeting (y 2)

Actualizado 18/05/2012 3:02:03 CET


- Neuroscience, including: Alzheimer's disease, multiple sclerosis,
neuropathic pain, epilepsy, depression
- Oncology including: anticancer therapies; tumour regression, tumour
suppression, antibodies, etc and supportive cancer therapies; pain relief, nausea
- Vascular/Immunological reaction including: acute coronary syndrome,
atherothrombotic disease, rheumatoid arthritis, psoriasis, Crohn's disease

With operations in the U.S., Asia, Europe and its domestic home market of Japan, Eisai employs more than 11,000 people worldwide. In Europe, Eisai undertakes sales and marketing operations in over 20 markets, including the United Kingdom, France, Germany, Italy, Spain, Switzerland, Sweden, Ireland, Austria, Denmark, Finland, Norway, Portugal, Iceland, Czech Republic, Slovakia, the Netherlands, and Belgium. For further information please visit our web site http://www.eisai.com About Morphotek

Morphotek(R), Inc., a subsidiary of Eisai, is a biopharmaceutical company specialising in the development of protein and antibody products through the use of a novel and proprietary gene evolution technology. The technology has been successfully applied to a broad variety of cell lines and organisms to yield genetically diverse offspring that are suitable for pharmaceutical product development in the areas of antibody therapeutics, protein therapeutics, product manufacturing, drug target discovery, and improved output traits for commercial applications. The company is currently focusing its platform on the development and manufacturing of therapeutic antibodies for the treatment of cancer, inflammation and infectious disease.

For more information, please visit http://www.morphotek.com.

1. Cortes J, O'Shaughnessy J, Loesch D, et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. The Lancet. 2011; 377: 914 -923.

2. Matsui J et al. Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumour MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res 2008; 14: 5459-65.

3. Matsui J et al. E7080, a novel inhibitor that targets multiple kinases, has potent antitumour activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer 2008; 122: 664-71.

CONTACT: Media Enquiries: Eisai Europe Ltd, Charlotte Andrews / CressidaRobson, 18 May. (0) - 7947-231513 / +44(0)790-831-4155, charlotte_andrews@eisai.net/ , cressida_robson@eisai.net ; Tonic Life Communications: Benjamyn Tan/ Leah Peyton, +44(0)207-798-9262 / +44(0)7788-191434,benjamyn.tan@toniclc.com / leah.peyton@toniclc.com

Mejora la comunicación de tu empresa con Europa Press Comunicación

Mejora la comunicación de tu empresa con Europa Press Comunicación